Phase 1 N=33 Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
Hypertension(HTN)
Primary: AUClast — 1.0360; 1.1606; 1.0266; 1.0902 Ratio(Comb/Alone)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors
Head and Neck Cancer
Primary: Number of Participants With Side Effects After Ad/PNP-F-araAMP Treatment — 12; 8; 8; 5 participants
Phase 1 N=17 An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
Lymphoma, Mantle-Cell
Primary: Correlation Coefficient Between Change From Baseline in Fluoro-L-thymidine Positron Emission Tomography (FLT-PET) Maximum Standard Uptake Value (SUVmax) and in…
Phase 1 N=10 Safety and Dialysability of Dotarem® in Dialysed Patients
End-stage Renal Failure
Primary: Dialysability of Dotarem® in Dialysed Patients — -88.2; -93.4; -97.1; -94.8 percent change in Gd concentration
Phase 1 N=20 Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Multiple Myeloma · Non-Hodgkin Lymphoma · Acute Myeloid Leukemia
Primary: Subjects With Treatment Emergent Adverse Events — 20 participants
Phase 1 N=20 LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
Breast Cancer
Primary: To Determine the Maximum Tolerated Doses (MTD) and Dose-limiting Toxicities (DLT) of LBH589 in Combination With Capecitabine When Administered to Patients With…
Phase 1 N=84 Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Relapsed Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6; 6; 8; 6 participants
Phase 1 N=141 Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
Schizophrenia · Mental Disorder · Nervous System Diseases
Primary: Number of Participants With Adverse Events (AEs). — 112; 4; 112; 2 participants
Phase 1 N=10 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Baseline Expanded Disability Status Score (EDSS) — 3.5 units on a scale
Phase 1 N=28 A Study of Cephalexin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 77.430; 76.374…
Phase 1 N=24 PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Actinic Keratosis
Primary: Change in Degree of Infiltration — 1.42 percentage change
Phase 1 N=28 A Study of Cephalexin Suspension in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 29.539; 35.857…
Phase 1 N=28 A Study of Cephalexin Capsules in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve of Cephalexin From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 19.102…
Phase 1 N=35 Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
Systemic Infections
Primary: Pharmacokinetic Parameters of Avibactam and Ceftazidime for Cohort 1 and 2: AUC — 35140; 219100; 33590; 212400 h*ng/mL
Phase 1 N=25 A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)
Type 2 Diabetes Mellitus
Primary: Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2 — 6; 7; 10; 12 Participants